Pipeline coverage

Nav1.7 Blockers- New Genre of Pain Relief Therapy

Posted on Updated on

Voltage-gated sodium channels are membrane proteins, a polypeptide chain of more than 1800 amino acids that conduct sodium ions at high rates. They are embedded in the plasma membrane and are actively present in the nerve and muscle cells used in the rapid electrical signaling. Nav channels are therapeutic targets for many cardiovascular and neurological disorders. The different subtypes of voltage gated sodium channel include Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7, Nav1.8 and Nav1.9 channels.

Nav1.7 is involved in early phases of neuronal electrogenesis. Mutations in Nav1.7 channel can caused Familial Rectal Pain (FRP) and Paroxysmal Extreme Pain Disorder (PEPD) in humans. Studies by James Cox and Geoff Woods et al. have demonstrated that Nav1.7 leads to pain signaling and generation in humans. Mutation in T2573A and T2543C in Nav1.7 can cause primary erythermalgia. Nav1.7 acts as a promising target in the pain perception pathway. Blockers of Nav1.7 channels have great potential as analgesics, and therapy for the treatment of chronic pain including dental pain, pain associated with osteoarthritis, erythromelalgia, diabetic neuropathy, peroxymal extreme pain disorder (PEPD), neuropathic pain and ocular pain. Benzazepinone, amino-thiazoles, amino-pyridines and isoxazoles are inhibitors of Nav1.7 that provide the desired treatment for pain with fewer side effects. ProTx-II isolated from tarantula Thrixopelma prurient is blocker of Nav1.7 channels. Peptides that are present in venoms of snakes and spiders are also the source ion channel blockers.

Currently, there are some major companies that involved in Nav 1.7 blocker drugs development including Amgen, Biogen, Genentech, Teva Pharmaceuticals, and Sumitomo Dainippon. These companies are in initial phase of development with drugs either in Preclinical stage of development or in Phase I stage.

These Nav 1.7 blockers are on the hit list of companies and it’s quite evident with active alliances and acquisitions that they are working with great hopes towards it. The joint venture of Purdue Pharma and AnaBios Corporation in the year 2015 is a sign that researchers have found this compound to be of great commercial value and hence companies are moving ahead in the domain of chronic pain treatment using AnaBios’ Phase-X technology. Not only this, in January 2016 Biogen acquired Convergence Pharmaceuticals that brings along Convergence’s Phase 2 chronic pain compound CNV1014802 to Biogen, thereby expanding their chronic pain portfolio.

Nav1.7 blockers have an edge over other conventional blockers as they are more targets specific and can also be used to deliver non-selective local anesthetic. Nav1.7 blockers prevent motor side effects that occur due to other pain relief therapies. Preclinical studies that are ongoing have shown satisfactory results till now with very few cases of adverse effects and in future we can assume that Nav1.7 blockers can come up as a new genre of pain relief therapy for future with much broader efficacy range and less adverse effects.

Insight by :
Anurag Mathur
Associate Analyst
DelveInsight Business Research

 

Advertisements

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Posted on

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 -A DelveInsight Report

Posted on Updated on

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback from clients.
PD-1and PDL-1 is the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.
Reports Highlights:
  • PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario
  • Collaborations & partnering deals
  • Current Prominent Research Areas and Key Players
  • Pipeline product profiles PD-1 and PD-L1 Inhibitors Technologies
  • Market Drivers and Barriers
Report Coverage:
40+ products, 30+ companies and 15+ different technologies
PD-1/PDL-1 Inhibitors report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. In addition, the report provides the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) along with the information on ongoing collaborations for the development of combinations regimens.
 PD-1/PDL-1 Inhibitors report report covers the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. The reports also cover Commercial Aspects such as the Current and Future Market, market drivers and barriers followed by SWOT Analysis
The Reports will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
DelveInsight is offering the Report at a price of USD 2,950 as a single user license, USD 5,900 as a site license andUSD 8,850 as a Global/Enterprise License.
For more information mail us at info@delveinsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

Posted on

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The report provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The Report gives insights on 30+ products with 15+ different technologies. It also includes around 20+ companies which are active in this field. DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 3,750 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

Phone: +91-11-45689769, +91 9650213330

Website: http://delveinsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

“Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” – A DelveInsight Report

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio.

Reports Highlights:

·      CAR-T cell Therapy Pipeline scenario
·      Collaborations & partnering deals
·      Current Prominent Research Areas and Key Players
·      Pipeline product profiles CAR-T Technologies and Targeted Antigens
·      Licensing opportunities
·      Market Drivers and Barriers

Report Coverage:

40+ companies,100+ products and 24 different technologies

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” emphasizes on the currently active CAR-T cell products in research and development. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens.

The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2,450 as a single user license, USD 4,900 as a site license and USD 7,350 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

Phone: +91-11-45689769, +91 9650213330

Website: http://delveinsight.com

 About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.
The Indication pipeline Insight Reports provides client with Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 products across the globe. It comprehensively includes:
  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 10 are in phase III, 25 in phase II, 49 in phase I, 2 in phase 0 13 in pre – clinical and 30 inactive and 6 are discontinued.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Head and Neck Squamous Cell Carcinoma helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

 

DelveInsight is offering the Report at a price of US 2,250 as a single user license, USD 4,500 as a site license and USD 6,750 as a Global/Enterprise License.
For more information on Pipeline Insight Reports, email at info@delveInsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now!

Posted on Updated on

assdd

Launch of DelveInsight’s Antibody-Drug Conjugate Report

DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives cdadadadadadore information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.

Around 253 ADCs in Oncology
Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.

Four Potential ADCs in Phase III Pipeline 

Companies are trying its already marketed ADC for different combinations and for different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.
Report Pricing
Single User License:  3500 USD
Site License: 7000 USD
Global License: 10500 USD
For more information email us at info@delveinsight.com or visit us at http://www.delveinsight.com
Ask for Sample Pages now!